Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Acq. announced
Appointed director
Quarterly results
Consulting agrmnt
|
|
Ardea Biosciences, Inc. (RDEA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/22/2012 |
8-K
| Quarterly results |
| 06/13/2012 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/05/2012 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 05/30/2012 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/24/2012 |
8-K
| Acquisition/merger/asset purchase announced |
| 04/02/2012 |
8-K
| Form 8-K - Current report |
| 03/09/2012 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results SAN DIEGO, March 9, 2012 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2011 financial results. “The proceeds of $157.6 million from our recent financing, added to our existing cash balance, put us in an excellent financial position,” commented Barry D. Quart, PharmD, Ardea's president and chief executive officer. “We believe these resources should fund operations beyond the estimated primary endpoint dates of all four of the planned Phase 3 studies of lesinurad that are now fully underway.” Recen..." |
|
| 01/31/2012 |
8-K
| Results of Operations and Financial Condition, Other Events |
| 01/09/2012 |
8-K
| Form 8-K - Current report |
| 12/22/2011 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/19/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/07/2011 |
8-K
| Form 8-K - Current report |
| 11/04/2011 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results SAN DIEGO, November 4, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the three and nine months ended September 30, 2011. “Since our last quarterly update, we have advanced our development program for lesinurad and continue to target commencing Phase 3 studies before the end of this year,” commented Barry D. Quart, PharmD, president and chief executive officer. “We completed formal End-of-Phase 2 meetings with the FDA and received clear feedback and reached agreement on key aspects of our proposed Phase 3 p..." |
|
| 09/07/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/05/2011 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results SAN DIEGO, August 5, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2011. “Since our last quarterly update, we presented exciting initial results from the ongoing extension portion of our Phase 2b trial of lesinurad demonstrating high rates of sustained uric acid lowering and patient response over week 28 of the study at all doses,” commented Barry D. Quart, PharmD, president and chief executive officer. “These results, together with the impressive efficacy and safety profile establis..." |
|
| 05/25/2011 |
8-K
| Form 8-K - Current report |
| 05/09/2011 |
8-K
| Quarterly results |
| 04/08/2011 |
8-K
| Form 8-K - Current report |
| 03/11/2011 |
8-K
| Form 8-K - Current report |
| 01/21/2011 |
8-K
| Form 8-K - Current report |
| 01/19/2011 |
8-K
| Form 8-K - Current report |
| 01/10/2011 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits |
| 01/06/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/18/2010 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/09/2010 |
8-K
| Form 8-K - Current report |
| 11/08/2010 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/22/2010 |
8-K/A
| Form 8-K - Current report [amend] |
| 10/07/2010 |
8-K
| Form 8-K - Current report |
| 09/17/2010 |
8-K
| Form 8-K - Current report |
| 08/06/2010 |
8-K
| Form 8-K - Current report |
| 06/18/2010 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/27/2010 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/10/2010 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/07/2010 |
8-K
| Quarterly results|
Docs:
|
"Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results SAN DIEGO, May 7, 2010 — Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus , today reported recent accomplishments and financial results for the first quarter ended March 31, 2010. “We are pleased to have accomplished a number of very important objectives since our last quarterly update,” commented Barry D. Quart, PharmD, president and chief executive officer of Ardea. “In March, we announced positive, preliminary top-line results from our completed Phase 2b monotherapy study of RDEA594 and, shortly thereafter, we were able to significantly strengthen our financial posit..." |
|
|
|
|